Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib

Does postoperative circulating tumor DNA (ctDNA) status predict survival among patients with stage III colon cancer treated with adjuvant celecoxib?This post hoc analysis used a clinically validated, tumor-informed assay to determine ctDNA status in 940 patients with stage III colon cancer and found that ctDNA negativity was highly associated with improved survival. Patients with ctDNA positivity demonstrated a survival benefit with adjuvant celecoxib, whereas patients with ctDNA negativity did not.These findings underscore the prognostic value of ctDNA and suggest it may help identify a subset of patients who benefit from adjuvant celecoxib alongside conventional chemotherapy.

Corresponding Author: Jonathan A. Nowak, MD, PhD, Department of Pathology, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (janowak@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.